Cereno Scientific avser genomföra en företrädesemission av units om cirka 400 MSEK med fokus på den globala fas IIb-studien EPIMODE och erhåller förlängd lånefinansiering om[...]

Cereno Scientific AB published this content on November 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 12, 2026 at 16:23 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]